Ozempic and vision loss: what the research actually shows
A small but striking study links semaglutide and tirzepatide to serious eye conditions, raising questions researchers say are worth taking seriously even if the risk remains low. Weight loss medications have reshaped how doctors approach obesity and blood sugar management. Ozempic and Zepbound, which contain semaglutide and tirzepatide respectively, have become […]
Celebrities who’ve taken Ozempic and GLP-1 weight loss drugs
Ozempic and its GLP-1 counterparts are no longer Hollywood’s best kept secret. What started as whispered speculation about sudden transformations on red carpets has turned into a growing chorus of celebrity voices speaking openly about weight loss medication. Their willingness to share is doing something quietly powerful and shifting the conversation from shame toward honesty. […]
The pros, cons, and considerations of taking ozempic or other drugs for weight loss
Ozempic has become one of the most talked about medications in recent memory, and for good reason. A growing number of people who spent years struggling with weight have finally found something that works. But behind the Ozempic hype is a more layered story, one that deserves a closer look before anyone rushes to their […]
FDA proposes cutting off affordable GLP-1 access for millions
A move by the U.S. Food and Drug Administration could significantly change how millions of Americans access some of the most widely used weight loss medications on the market. On April 30, the FDA announced a proposal to remove glucagon-like peptide-1 (GLP-1) receptor agonists including semaglutide and tirzepatide, the active ingredients in Ozempic, Wegovy and […]
Ozempic’s New Pill Form Could Change Who Has Access
Novo Nordisk has begun selling an oral version of semaglutide in the United States under the Ozempic name, a move that extends one of the most recognized drug brands in recent memory into a format that does not require an injection. The pill became available on May 4, 2026, at more than 70,000 pharmacies nationwide, […]
Ozempic breath is a real problem: here’s what causes it
GLP-1 receptor agonist medications like Ozempic and Wegovy have become some of the most talked about drugs in recent years, largely praised for their effectiveness in managing type 2 diabetes and supporting weight loss. But alongside the well known gastrointestinal complaints nausea, bloating, and constipation a lesser discussed side effect has been making its way […]
New study finds 1 gene variant that boosts GLP-1 results
GLP-1 receptor agonists like semaglutide and tirzepatide have become some of the most talked about medications in modern medicine, reshaping how millions of people approach weight loss. But a sweeping new study suggests that the results people experience may have less to do with willpower or lifestyle and more to do with what is written […]
Is Ozempic butt real? The side effects that matter most
Ozempic has become one of the most talked-about prescription medications in recent years, attracting attention not just from people managing type 2 diabetes the condition it was originally approved to treat but also from those seeking help with weight loss. And while the drug has delivered real results for many, it also comes with a […]
Mounjaro vs. Wegovy: What happens when you stop them
An estimated 1.6 million people in the United Kingdom are currently taking weight-loss drugs, and the numbers continue to grow. While some access these treatments through the National Health Service, the majority purchase them privately. The two most widely used options are Mounjaro and Wegovy injectable medications that have changed the conversation around obesity treatment. […]
The alarming truth about stopping GLP-1 drugs and heart health
For patients with type 2 diabetes who take GLP-1 medications, the cardiovascular benefits do not come quickly but they can disappear fast. That is the central and sobering finding of a newly published study in the British Medical Journal, which followed more than 333,000 adults with type 2 diabetes over three years to examine what […]